Background: Patient reported-outcomes [PROs] are a major therapeutic goal in inflammatory bowel disease [IBD].
Introduction
Ulcerative colitis [UC] and Crohn's disease [CD] are chronic, disabling inflammatory bowel diseases [IBD] . 1 Patient-reported outcomes [PROs] are now becoming important endpoints in clinical trials in the field of IBD 2 and were recently selected as treatment targets by an expert group of 28 IBD specialists. 3 A number of disease-specific and generic questionnaires have been developed and validated for the assessment of PROs (including quality of life [QoL] , fatigue, work productivity, disability, and depression/anxiety) in IBD. 1, [4] [5] [6] [7] [8] [9] QoL is the most intensively studied PRO in IBD; it is usually assessed with the Inflammatory Bowel Disease Questionnaire [IBDQ] and/or the non disease-specific Short Form-36 [SF-36] questionnaire. 2 It is noteworthy that the Short Inflammatory Bowel Disease Questionnaire [SIBDQ] score is correlated with the IBDQ score. . 10 Fatigue is strongly associated with poor health-related QoL, disability, and depression similarly in CD and UC even when controlling for disease activity. 11 The burden of IBD has an impact on work productivity. In Swedish patients, the mean loss in productivity, related to absenteeism and presenteeism, has been estimated at 5938euros [5580 euros, 2007] per patient and per year. 12 The Work Productivity and Activity Impairment Questionnaire [WPAI] 13,14 measures absenteeism, presenteeism, work productivity los,s and overall activity impairment, and has been used in studies of IBD. [15] [16] [17] The Inflammatory Bowel Disease Disability Index [IBD-DI] has recently been validated in a population-based study. 8 The mean (interquartile range [IQR] Depression and anxiety are generally evaluated by rating the Hospital Anxiety and Depression Scale [HADS] ; the scale ranges from 0 to 21 for anxiety and for depression, with score of 0 to 7 for a 'normal' person. 9, 18 The primary objective of the present study was to assess for the first time the overall disease burden of IBD by administering six validated questionnaires on PROs to members of the French national IBD patients' association. We also investigated demographic and disease-related factors associated with these PROs.
Methods

Study population
We performed a cross-sectional study of patients affiliated with the French national IBD charity (the Association Francois Aupetit [AFA] 19 ).The AFA focuses solely on patient support and research in IBD. 19 All members of the AFA have IBD or have children with IBD. Only adult [aged over 18] patients affiliated with the AFA were invited to participate in the present study.
The questionnaire document and the data collection procedures
The AFA's head office posted the questionnaire document to all prospective participants. The document included all the items from validated questionnaires for the assessment of the The document also included some simple questions on the patient's demographic and disease-related characteristics, such as age at the time of study, age at diagnosis, gender, socioeconomic status [in education, unemployed, retired, or in paid employment], smoking status, and current and previous medications. Clinical disease activity was measured using the Harvey-Bradshaw Index [HBI] in patients with CD 20 and the Simple Clinical Colitis Activity Index [SCCAI, also known as the Walmsley score] 21 in patients with UC. The completion time was estimated to be 30 min. Patients were provided with a prepaid envelope [to increase the return rate] and were asked to post the completed document back to the AFA's head office.
Data collection and statistical analyses
All completed documents were sent by the AFA's head office to the referral centre in Nancy. Two researchers [NW and CA] entered the questionnaire data. After verification of the data entry by NW, HS, CGR, and LPB, statistical analyses were performed using SAS software [version 9.4 More than half of the 1185 patients had previously taken oral steroids [53.9%], whereas only 8.7% of the study population were doing so at the time of the study. At the time of the study, 26.2% of the patients were taking thiopurine, 31.4% were taking tumour necrosis factor [TNF] antagonists, and 5.4% were taking methotrexate (either alone or [in 9.5% of these cases] combined with other drugs); 30% of the patients had a history of surgery, and 8% had a stoma. The stoma was permanent in 41.3%.
Results
Characteristics of the respondents
Patient-reported outcomes
The data on PROs in the AFA cohort are summarized in Table 2 
Correlations between PROs
All the PCCs for PRO scores [ Figure 1 
Discussion
To the best of our knowledge, the present study is the first to have studied all the dimensions of PROs in a large, nationwide cohort of IBD patients. The SIBDQ and SF-36 scores recorded in clinical trials of biologics 2 appear to be similar to the score in our survey[in which 31.4% of patients were being treated with TNF antagonists at the time of the study]. The high proportion of UC patients exposed to anti-TNF therapy [22%] might be explained by the inclusion of UC patients with more severe disease even though other baseline characteristics such as colectomy rate [8.1%] do not support that.
In a recent review, fatigue was reportedly prevalent in 41% to 48% of patients with IBD in remission and in 86% of those with active disease, 10 when considering both randomized controlled trials [22] [23] [24] and clinical practice. 22, [25] [26] [27] Only two population-based studies have been published to date. 25, 28 In a recent American study of220 patients with IBD, fatigue [a FACIT-F score ≤30] was reported only in 26.4% of the participants, 11 and fatigued patients reported greater levels ofwork impairment and activity impairment on the WPAI questionnaire. 11 Despite similar levels of moderate-to-severe disease activity in patients with CD and UC in our cohort [about 30%], the self-reported prevalence of fatigue was significantly greater in our study [47.4%] than in the American study, possibly due to cultural 8 However, disability was moderate to severe in almost one-third of our study population.
The WPAI data reported in our study highlighted the economic burden of IBD. Absenteeism, presenteeism, and work productivity loss were moderate to severe in about 10%, 50%, and 50% of the surveyed patients, respectively. However, we defined these thresholds empirically on the basis of estimated clinically relevance, and so these values may vary from one country to another. In CD, the estimated median duration of absenteeism is 120 days; when combined with presenteeism [i.e. attending work while sick], this results in an annual cost of €5938 per patient. 12 In the ACCENT I trial, the baseline full-and part-time employment rates were 48% and 13%, respectively; 39% of the patients were unemployed and 25% were receiving disability benefits.
The prevalence of depression is estimated to be three times greater in IBD than in the general population. 29 The median HADS-D and -A scores in our study were similar to the literature values for IBD. In contrast, the prevalence of depression in our cohort was higher [ 33 However, correlations between PROs in patients with IBD have never been assessed. In the EPIMAD registry, there was a strong correlation between the IBD-DI on one hand and the IBDQ score [PCC: -0.82], the SF-36 Mental score [-0.71], and the SF-36 Physical score [-0 .61] on the other. 8 To the best of our knowledge, the BIRD study is the first to have assessed the correlations between all the main PROs in IBD.
Our study had several other strengths. First, this was largest nationwide study of all dimensions of PROs in the context of IBD. Second, only validated questionnaires were used. Third, we identified female gender, employment status [particularly unemployment], and disease activity as the main associated factors for all PROs. Interestingly, our study is the first to have identified a significant association between treatment with TNF antagonists at time of study on one hand and severe fatigue (OR [95% CI] = 1.45 [1.07; 1.95]; p = 0.015) and work productivity loss (1.85 [1.31; 2.60]; p <0.001) on the other. Anti-TNF use is likely a surrogate marker of more severe and more disabling disease. The correlations between PROs scores are clinically credible and, thus, straighten our study's overall results. Importantly, the characteristics of our study population [such as the prevalence of mild-to-moderate disease and a history of surgery] were similar to those observed in the EPIMAD French population-based study, 8 suggesting that our study was free of significant selection bias.
Our study had some limitations. First, all patients completed the questionnaires at home; self-reporting may lead to a degree of interpretation bias. Also, the number of questionnaires [n = 6] could have been too high to keep patients' attention focused through all of them. Second, some of questionnaires [such as the IBD-DI] or disease activity [HBI] questionnaires, have not been validated for self-reporting, in contrast to SCCAI. 34 Last, it remains to be seen whether our findings for France can extrapolated to other countries and other parts of the world. Low response rate and biased population are other limitations of this study.
In conclusion, around half of a large French cohort of patients with IBD had poor QoL, severe fatigue, severe work impairment, and depressive symptoms. The disability was moderate to severe and anxiety was present in a third of cases. Female gender, unemployment, and severe disease activity were associated with the worst PROs. A tight monitoring of these patients together with a rapid step-up approach are probably the best way to prevent disability and to help patients return to a normal life. Our results highlight the weight of the burden of IBD in patients' daily lives. A comprehensive assessment of PROs should be recommended in clinical practice. The associated factors identified here may enable targeted interventions to be developed for IBD patients.
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